Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Nivolumab plus cabozantinib (NIVO + CABO) was approved for first-line treatment of advanced renal cell carcinoma (aRCC) based on superiority versus sunitinib (SUN) in the phase III CheckMate 9ER trial (18.1 months median survival follow-up per database lock date); efficacy benefit was maintained wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESMO open 2024-05, Vol.9 (5), p.102994, Article 102994
Hauptverfasser:	Powles, T., Burotto, M., Escudier, B., Apolo, A.B., Bourlon, M.T., Shah, A.Y., Suárez, C., Porta, C., Barrios, C.H., Richardet, M., Gurney, H., Kessler, E.R., Tomita, Y., Bedke, J., George, S., Scheffold, C., Wang, P., Fedorov, V., Motzer, R.J., Choueiri, T.K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anilides - pharmacology Anilides - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use cabozantinib Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Female Follow-Up Studies Humans IMDC immunotherapy Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - pathology Male Middle Aged nivolumab Nivolumab - pharmacology Nivolumab - therapeutic use phase III Progression-Free Survival Pyridines - pharmacology Pyridines - therapeutic use renal cell carcinoma Sunitinib - pharmacology Sunitinib - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!